| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Medical | 112.6 | 40.7 | 67.1 | 16.9 | 130.8 | | | |
| Industrial | 8.4 | 10.7 | 11.0 | 23.0 | 16.2 | | | |
| Other | | | | | | | | 2.6 |
| Other | 272.6 | 330.4 | 265.5 | 254.2 | 80.9 | | | 100.4 |
| Total revenues | 393.7 | 381.9 | 343.5 | 294.1 | 227.9 | 171.5 | 130.6 | 103.0 |
| Revenue growth [+] | 3.1% | 11.2% | 16.8% | 29.1% | 32.9% | 31.3% | 26.8% | 12.1% |
| Medical | 176.9% | -39.3% | 295.9% | -87.0% | | | | |
| Industrial | -21.4% | -2.5% | -52.2% | 42.4% | | | | |
| Cost of goods sold | 143.3 | 128.9 | 114.5 | 108.9 | 91.5 | 64.3 | 51.6 | 41.7 |
| Gross profit | 250.4 | 253.0 | 229.0 | 185.3 | 136.4 | 107.2 | 79.1 | 61.3 |
| Gross margin | 63.6% | 66.2% | 66.7% | 63.0% | 59.8% | 62.5% | 60.5% | 59.5% |
| Selling, general and administrative | 183.0 | 172.8 | 147.1 | 133.0 | 111.6 | 84.4 | 62.6 | 47.6 |
| Research and development | 69.2 | 55.5 | 53.1 | 42.5 | 37.4 | 26.7 | 20.3 | 16.9 |
| Other operating expenses | 3.8 | 3.2 | 3.4 | 2.6 | 4.2 | 3.1 | 3.1 | 3.1 |
| EBITDA [+] | 20.8 | 45.0 | 48.6 | 25.9 | -0.6 | 2.4 | 0.9 | 2.2 |
| EBITDA growth | -53.7% | -7.6% | 87.6% | -4181.7% | -126.7% | 151.6% | -56.3% | -190.8% |
| EBITDA margin | 5.3% | 11.8% | 14.2% | 8.8% | -0.3% | 1.4% | 0.7% | 2.1% |
| Depreciation and amortization | 22.5 | 20.3 | 19.8 | 16.1 | 12.0 | 6.2 | 4.8 | 5.4 |
| EBITA | -1.7 | 24.7 | 28.9 | 9.8 | -12.6 | -3.9 | -3.9 | -3.2 |
| EBITA margin | -0.4% | 6.5% | 8.4% | 3.3% | -5.5% | -2.2% | -3.0% | -3.1% |
| Amortization of intangibles | 3.8 | 3.2 | 3.4 | 2.6 | 4.2 | 3.1 | 3.1 | 3.1 |
| EBIT [+] | -5.6 | 21.4 | 25.4 | 7.2 | -16.8 | -7.0 | -7.0 | -6.3 |
| EBIT growth | -125.9% | -15.6% | 252.0% | -142.9% | 140.8% | 0.3% | 10.1% | -33.3% |
| EBIT margin | -1.4% | 5.6% | 7.4% | 2.5% | -7.4% | -4.1% | -5.3% | -6.1% |
| Non-recurring items [+] | 24.3 | 1.9 | | -2.8 | 14.0 | 12.7 | 26.2 | |
| In-process research & development | | | | -2.9 | 14.0 | 12.7 | 26.2 | |
| Interest expense, net [+] | 25.6 | 7.1 | 6.2 | 1.7 | -0.8 | -4.7 | -5.6 | 3.1 |
| Interest expense | 26.9 | 8.0 | 7.1 | 2.2 | 0.0 | 0.1 | 0.2 | 4.0 |
| Interest income | 1.3 | 0.9 | 0.9 | 0.5 | 0.8 | 4.8 | 5.8 | 1.0 |
| Other income (expense), net [+] | 4.7 | -2.8 | -1.1 | -0.9 | 2.3 | 1.9 | 1.5 | 1.1 |
| Gain (loss) on debt retirement | | -5.0 | | | | | | |
| Gain (loss) on foreign currency transactions | -1.2 | -0.6 | -1.0 | -0.9 | 2.3 | | | |
| Other | 5.9 | 2.7 | -0.1 | 0.0 | | -0.1 | | 0.0 |
| Pre-tax income | -50.8 | 9.7 | 18.1 | 7.3 | -27.8 | -13.1 | -26.1 | -8.3 |
| Income taxes | -16.3 | 1.7 | -20.0 | 2.1 | 1.2 | 0.6 | 0.5 | 0.3 |
| Tax rate | 32.1% | 17.2% | | 28.5% | | | | |
| Net income | -34.5 | 8.0 | 38.1 | 5.2 | -29.0 | -13.7 | -26.6 | -8.6 |
| Net margin | -8.8% | 2.1% | 11.1% | 1.8% | -12.7% | -8.0% | -20.3% | -8.3% |
| |
| Basic EPS [+] | ($0.63) | $0.15 | $0.73 | $0.10 | ($0.60) | ($0.29) | ($0.66) | ($0.41) |
| Growth | -523.1% | -79.4% | 602.7% | -117.3% | 106.8% | -56.2% | 61.0% | -82.0% |
| Diluted EPS [+] | ($0.63) | $0.15 | $0.70 | $0.10 | ($0.60) | ($0.29) | ($0.66) | ($0.41) |
| Growth | -536.8% | -79.2% | 609.5% | -116.4% | 106.8% | -56.2% | 61.0% | -82.0% |
| |
| Shares outstanding (basic) [+] | 54.3 | 53.5 | 52.3 | 50.6 | 48.4 | 47.4 | 40.3 | 21.0 |
| Growth | 1.6% | 2.2% | 3.5% | 4.4% | 2.2% | 17.7% | 91.9% | 213.5% |
| Shares outstanding (diluted) [+] | 54.3 | 55.2 | 54.6 | 53.3 | 48.4 | 47.4 | 40.3 | 21.0 |
| Growth | -1.5% | 1.1% | 2.5% | 10.1% | 2.2% | 17.7% | 91.9% | 213.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |